Visual storytelling for medical publications
2022-10-04 10:26
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Analysis from
#KATHERINE
trial indicates
#HER2
positive
#breastcancer
patients benefit from adjuvant trastuzumab emtansine even when HER2 status switched after neoadjuvant chemo
https://go.nature.com/3DJtqwS
#VisualAbstract
@drmaxmano
@mdwrtcom